Ultragenyx Pharmaceutical (RARE) Shares are Up 0.21%

Ultragenyx Pharmaceutical (RARE) : Traders are bullish on Ultragenyx Pharmaceutical (RARE) as it has outperformed the S&P 500 by a wide margin of 23.87% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.21% in the last 1 week, and is up 25.15% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 11.11% and the 50-Day Moving Average is 14.53%. Ultragenyx Pharmaceutical (NASDAQ:RARE): On Fridays trading session , Opening price of the stock was $68 with an intraday high of $68.29. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $64.52. However, the stock managed to close at $66.54, a loss of 2.65% for the day. On the previous day, the stock had closed at $68.35. The total traded volume of the day was 645,250 shares.


The company Insiders own 10.1% of Ultragenyx Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.41% . Institutional Investors own 94.12% of Ultragenyx Pharmaceutical shares. During last six month period, the net percent change held by insiders has seen a change of -9%. Also, Piper Jaffray initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE). The current rating of the shares is Overweight, according to the research report released by the firm. The brokerage firm announces the price target at $70 per share. The rating by the firm was issued on July 7, 2016.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.